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Pharmacogenetics is considered as a prime example of how personalized medicine nowadays can be put into practice. However,
genotyping to guide pharmacological treatment is relatively uncommon in the routine clinical practice. Several reasons can be
foundwhy the application of pharmacogenetics is less than initially anticipated, which include the contradictory results obtained for
certain variants and the lack of guidelines for clinical implementation. However, more reproducible results are being generated, and
eﬀorts have been made to establish working groups focussing on evidence-based clinical guidelines. For another pharmacogenetic
hurdle, the speed by which a pharmacogenetic pro�le for a certain drug can be obtained in an individual patient, there has been a
revolution in molecular genetics through the introduction of next generation sequencing (NGS), making it possible to sequence a
large number of genes up to the complete genome in a single reaction. Besides the enthusiasm due to the tremendous increase of our
sequencing capacities, several considerations need to be made regarding quality and interpretation of the sequence data as well as
ethical aspects of this technology.is paper will focus on the diﬀerent NGS applications that may be useful for pharmacogenomics
in children and the challenges that they bring on.
1. Introduction
Pharmacogenetics refers to the in�uence of DNA variants
on drug response, the knowledge of which can facilitate
selection of the optimal drug, dose, and treatment duration
and avert adverse drug reactions [1]. Several demonstrations
have been given on the diﬀerences in response to drugs
between children and adults [2]. ese include diﬀerences
in drug metabolism and gene expression, the latter being
a highly dynamic process functioning from the neonatal
period over childhood into adult life. ough the number
of studies speci�cally devoted to the pediatric population is
still limited compared to adults, an increasing number of
genes are being identi�ed in which variants have an in�uence
on pharmacological treatment of childhood diseases [3].
e identi�cation of variants in novel genes as well as the
validation of their functional eﬀects will further increase our
ability to predict drug treatment response in children; at the
same time, the clinical implementation of this knowledge
will demand an e�cient diagnostic approach to �rst identify
a pharmacogenomic pro�le in an individual patient in a short
period of time, next to evidence-based clinical guidelines to
facilitate decision making based on the genotype [4].
e current golden standard for detecting pathogenic
variants—single nucleotide variations or small indels—is
Sanger sequencing [5, 6]. Developed in the late 70s by
Frederick Sanger, an English biochemist, the technique
has currently been optimized to evaluate variations in
PCR-ampli�ed DNA fragments with high sensitivity and
speci�city. e ma�or disadvantages of Sanger sequenc-
ing—particularly in a domain such as pharmacogenetics
where for a speci�c drug variants in multiple genes can
be, either independent of or in interaction with each other,
involved—are that each novel genetic test needs optimization
and turn-around times for each gene analysis can be relatively
long, certainly if therapeutic decisions would be based on
these results. Together with the sometimes ambiguous evi-
dence for the eﬀect of certain variants and the lack of robust
validation and clinical guidelines, this technical hurdle has
been one of the reasons that genotyping to inform clinical
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decisions regarding pharmacological treatment is not widely
practiced to date.
e introduction of next generation sequencing (NGS)
brought about a technological revolution among genetic
screening tools, as it now becomes possible to screen the
whole exome—the coding regions of ourDNA—and even the
complete genome in a single experiment [7–9]. e increase
of technological capacities and decrease of costs involved in
such analysis have resulted in successful implementation of
exome sequencing as a research tool, particularly to identify
novel genes for rare disorders [10, 11]. Causal genes for,
for example, the Freeman-Sheldon (OMIM no. 193700) or
the �abuki syndrome (OMIM no. 147920) were identi�ed
by combining whole exome sequencing data from diﬀerent
patients with a typical phenotype of these conditions [12].
ey demonstrate that it is possible to capture exomic vari-
ation and identify pathogenic variants using bioinformatic
tools. Since then, several other examples have been reported.
Because of this success, these screening techniques are
slowly starting to make their way as a diagnostic tool.
Certainly for complex diseases for which several genes have
been identi�ed—the sequence analysis of which is laborious,
time consuming, and expensive—the idea of sequencing all
23.000 genes in the exome in a single reaction is an alluring
alternative. Similarly, in a �eld such as pharmacogenetics,
with diﬀerent variants in diﬀerent genes in�uencing the
�nal drug response in an individual patient, such parallel
sequencing techniques can provide the promptness which
would be required in a clinical setting. is shi to the
more extensive screening assays has induced an evolution
from pharmacogenetics to pharmacogenomics [3]. Besides
the excitement surrounding these technical innovations, it
has become clear that NGS applications also present several
challenges.ese include not only the quantity of data which
is generated, its analysis, and interpretation but also ethical
and legal aspects. In the pediatric population, the latter have
very particular properties as a consequence of the incapacity
of the child to give informed consent himself and of the
predictive character of the interpreted sequence data which
may go beyond the initial clinical question.
In this paper, we will consider the characteristics of NGS,
the diﬀerentmeans by whichNGS technology can be applied,
and set out a concept that we think would be feasible to
use NGS-based pharmacogenetics in a present-day clinical
pediatric setting.
2. Genomes, Exomes, and the Variation within
e human genome is the entirety of an individual’s
hereditary information, including both the coding and
noncoding regions of DNA and RNA, while the human
exome encompasses the coding regions of the genes—the
exons—equivalenting ∼1%-2% of the total haploid genomic
sequence [12, 13]. Since the establishment of the reference
genome and subsequent sequencing of several individual
genomes, insights have emerged on the signi�cant variation
present in the genome within and between diﬀerent eth-
nicities. is variation can be roughly divided into simple
T 1: Genomic variation in an individual in numbers. All
data is given for an individual exome or genome. e number of
nonsynonymous variants, which induce a change in amino acid, has
been speci�ed as these are more likely to have a functional eﬀect
than synonymous variants (where the amino acid remains the same
despite the nucleotide change), although functional synonymous
variants have been described.
Number of variants
Similarity between two individual
genomes 99.5%
Whole genome sequencing variant
uptake
3,5 million SNP variants
1000 large CNVs
Whole exome sequencing variant
uptake 20.000–100.000 variants
Coding variants in the genome 20.000–25.000 variants
Nonsynonymous coding variants in
the genome 9.000–11.000 variants
nucleotide variations on one hand and structural variation
on the other [12]. e �rst include single nucleotide poly-
morphisms (SNPs) and small insertions/deletions (indels)
which have been surveyed in large groups of individuals,
resulting in, for example, dbSNP, a database of over 10 mil-
lion common variants in diﬀerent ethnic groups. Increased
knowledge on the architecture of the genome revealed,
however; the spectrum of variation was much broader than
these nucleotide changes, referred to as structural variation.
is includes not only inversions and copy number variations
(CNVs, i.e., deletions and duplications) but also, for example,
the presence of stretches of megabases of DNA unique to a
single personal genome. It has become clear that structural
variation in the genome is unexpectedly high andmuchmore
complex than previously anticipated (Table 1). In pharma-
cogenomics, both single nucleotide variants and structural
variation such as CNVs have been shown to contribute to
the drug response of an individual [14, 15]. e pleiotropy
by which this variation occurs has an impact on the identi-
�cation of functional variants for drug response and on the
analysis and interpretation of genomic screening assays.
3. Next Generation Sequencing
Following the Human Genome Project, which set out to
sequence the three billion nucleotides of the human genome,
several high throughput technologies were developed.
Among these, NGS has known a rapid evolution in a few
years time, increasing throughput and reducing costs by
continuous improvement of several analysis platforms
[7, 9, 16, 17]. Although all are based on the principle of
massive parallel sequencing, the speci�c work�ow of NGS
depends on the platform that is being used; one of these
techniques which demonstrates excellently the meaning of
massive parallel sequencing was developed by Margulies et
al. (Figure 1) [6, 9, 18]. In summary, aer fragmentation of
the genomic DNA, these fragments are bound to tiny beads
under speci�c conditions so that only one DNA fragment can
bind to a speci�c bead.ese beads are encased in droplets of
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F 1: Schematic representation of the principles ofmassive parallel sequencing using beads. Double-strandedDNA (a) is fragmented into
single-stranded DNA (b) which is subsequently coupled, via adaptors, to agarose beads by oligonucleotides complementary to the adaptor
(c). ese beads are submerged in an emulsion where ampli�cation of the single DNA fragment occurs (d). Subsequently, the bead is placed
into a well (e), already equipped with all reagents for sequencing (small beads). Within these wells, parallel sequencing of the diﬀerent DNA
fragments occurs, resulting in the generation of the genetic code of the fragment (f).
oil, containing all reactants necessary to amplify the DNA via
polymerase chain reaction (PCR). In this way, each bead ends
up with about 10 million copies of the initial DNA fragment.
For sequencing of these fragments, the beads are loaded
into a well plate—one bead per well—and sequenced by “the
sequencing-by-synthesis method” (determination of the
sequence by addition of nucleotides to the complementary
strand). Again, all reagents for the sequencing reaction are
already present in each well.
General limitations of massive parallel sequencing
include error rate, which is higher than Sanger sequencing,
warranting con�rmation of identi�ed causal variants by
conventional sequencing methods [6, 11, 19]. Further, the
quality of the sequence data or so-called coverage (i.e.,
to which extent is every nucleotide of the sequence of
interest—whether it is a selected set of genes or the whole
genome—reliably analyzed) depends on the sequence depth.
Valid results can be obtained from 40- to 80-fold sequence
depth, meaning that every nucleotide is sequenced 40 to
80 times [9, 20]. e higher the coverage, the more reliable
the result, but also the more expensive and laborious will
the analysis be as more sequencing needs to be done. e
importance of optimizing coverage of current NGS assays
in pharmacogenetics was recently demonstrated in a meta-
analysis which evaluated the eﬃciency of current platforms
in the analysis of 253 pharmacogenes. It was shown that
a maximum of 85% of coverage of these genes could be
obtained, while maximally 30% of missense polymorphisms
were covered [20]. is underscores the limitations of
genome-wide methods and the challenges and priorities for
further optimizing NGS assays.
4. Applications of NGS
NGS can be used in a targeted manner or can be applied
as a whole exome of whole genome diagnostic tool. Every
one of these approaches has its advantages and weaknesses
which will be discussed in the following, with respect to
pharmacogenomics in children.
4.1. Targeted Assays. In a targeted assay, NGS is used for
parallel sequencing of a selection of genes. ere are two
ways to go about selecting the genes of interest, which
determines the molecular technique that will be applied:
either a microarray-based target enrichment approach or a
targeted analysis of whole exome/genome sequencing (WES
andWGS, resp.) can be used. In the �rst, direct hybridization
of the patient’s DNA to an oligonucleotide array, containing
probes complementary to the selection of target genes,
is performed and then analyzed by NGS, thus generating
sequence data only of the genes of interest [16, 21]. In the
second approach, sequence data of the complete exome or
genome is generated, but a�erwards only the speci�c genes of
interest are bioinformatically selected and analyzed further,
while the remaining sequence is disregarded [9, 17].
e major advantage of the array-based target enrich-
ment assays is that these selective tests can be optimized to
have full coverage of the genes of interest, hence reaching
high sensitivity and speci�city. �oreover, for each gene it is
possible to design the array to just cover the sequence (exon,
intron or promotor) in which a particular SNP is present.
Further, by generating sequence data only of the genes
of your interest, the risk for incidental �ndings or ethical
issues on generated but unanalyzed sequence data—both
discussed in the following—is minimized. A good pharma-
cogenomic example of such an analysis would be couma-
rine treatment. e drug response to warfarin—a paradigm
for drugs with a narrow therapeutic index—is determined
by variants in several genes, including VKORC1, GGCX,
CYP2C9 and, CYP4F2 [22–24]. Among these, VKORC1
and GGCX encode key enzymes (VK-oxide reductase and
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F 2: Vitamin K cycle and warfarin metabolism. Inactive zymogens, among which are the VK-dependent coagulation factors II, VII,
IX, and X, are activated by gamma-carboxylation by the gamma-glutamyl carboxylase (GGCX). e cofactor for this carboxylation step is
VK, which is transformed into VK epoxide. is epoxide is then reduced by the VK-epoxide reductase of VKORC1 to quinone. Warfarin
speci�cally blocks the initial reduction step, while CYP4F2 catalyzes the formation of hydroxyvitamin K out of quinone.
gamma-glutamyl carboxylase; resp.) of the vitamin K (VK)
cycle, the metabolic process—essential for activation of VK-
dependent coagulation factors II, VII, IX, and X—which is
blocked by warfarin (Figure 2) [25]. Cytochromes P450 2C9
and P450 4F2 are important in the metabolization of the
drug, catalyzing the warfarin S-enantiomer into its inactive
metabolites (CYP2C9) or oxidase VK1, the essential cofactor
of the VK cycle (CYP4F2) [24, 26].
An important observation is that the functional variants
in, for example, the VKORC1 gene reside mostly in noncod-
ing regions such as the introns and promotor of the gene [22].
Contrary to exome analysis, where only the coding regions
are sequenced, a targeted array-based assay can bemaximally
optimized to cover both the coding and non-coding regions
of these 4 genes, thus resulting in a maximum of relevant
information in a single reaction.
Nevertheless, it must be remembered that drugs such
as warfarin, where most of the variance in metabolism and
clearance can be captured by analyzing a handful of genomic
variants, represent only a proportion of drugs with a narrow
therapeutic index; for many other drugs, this will not be the
case, confronting us with the main limitation of this type of
targeted analysis which is the limited �exibility in design. It
can be expected that formany drugs, novel genes and variants
will be discovered which will have a pharmacogenomic
eﬀect in addition to the ones known to date. ough this
number may be rather small for a very speci�c topic such as
warfarin biology, the pharmacogenetics of ADHD or asthma
treatment—for both of which variants in non-coding regions
were described (Table 2)—will likely expand signi�cantly in
the years to come [3, 27–30].
is implies that with every newly identi�ed gene, the
assay needs to be adjusted or updated to obtain the highest
yield of useful information. ough novel generation arrays
have already become more “user friendly” to expand the
number of targeted genes, it still does not come near the ease
by which additional genes can be analyzed in a prospective
T 2: Identi�ed pharmacogenes in ADHD and asthma.
Gene Variants
Asthma
ADRB2 p.Arg16Gly, p.Gln27Glu
AC9 p.Ile772Met
CRHR1 c.122-1310C > A (intronic)
TBX21 p.His33Gln
LTC4S g.24030224A > C (promotor)
CYSLTR1 p.Phe309Phe
ALOX5 5′ UTR
GSDML c.236-1199G > A (intronic)
ADHD
DRD4 48 bp allele
DAT1 3′ UTR
5-HTT del-1212-1255 (promotor)
SNAP-25 3′ UTR
COMT p.Val158Met
ADRA2A g.31585029G > C
ADRB2: agonists of beta-2 adrenergic receptor; AC9: adenylyl cyclase
type 9; CRHR1: corticotropin releasing hormone receptor 1; TBX21: T-
box 21; LTC4S: leukotriene C4 synthase; CYSLTR1: cysteinyl leukotriene
receptor 1; ALOX5: arachidonate 5-lipoxygenase; GSDML: gasdermin B;
DRD4: dopamine receptor 4; DAT1: dopamine transporter 1; 5-HTT:
serotonin transporter; SNAP-25: synaptosomal-associated protein; COMT:
catechol-O-methyltransferase; ADRA2A: adrenergic alpha2-receptor; UTR:
untranslated region.
way using WES or WGS. When applying targeted exome
analysis, whole exome sequencing is performed resulting in
sequencing data of 23.000 genes. Subsequently, only those
genes of interest are �ltered out to analyse variants. When
a novel gene is identi�ed, it is easy to go back to the
initial sequence data, access the sequence of the new gene,
and analyze variants. However, as mentioned, the major
limitation of this approach is the lack of good sequence
data of non-coding regions, making this technique only
useful to obtain a pharmacogenetic pro�le for those drugs of
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T 3: Identi�ed pharmacogenes in childhood ALL. All are
aﬀecting the coding regions of the respective genes.
Gene Variants
TPMT p.Ala80Pro, p.Ala54Tyr, p.Tyr240Cys
GSTT1 Large deletion
GSTM1 Large deletion
GSTP1 p.Ile105Val
MTHFR p.Ala222Val, p.Glu429Ala
GGH p.r151Ile
TMPT: thiopurine methyltransferase; GST: glutathione-S-transferase fam-
ily; MTHFR: methylenetetrahydrofolate reductase; GGH: gamma-glutamyl
hydrolase.
which the relevant variants are in coding regions. One such
example is the treatment of acute lymphoblastic leukemia
(ALL) in children [2, 31]. As chemotherapeutic agents are
oen given at a dose near the toxic range and signi�cant
interindividual variability can be seen in eﬀect and adverse
reactions, pharmacogenetics can aid in tailoring treatment
to the speci�c needs of the patient. Several polymorphisms
in enzymes which metabolize chemotherapeutics have been
shown to alter treatment response (Table 3), all of which aﬀect
the coding regions of the respective genes. In ALL patients,
targetedWES can be an option as all relevant variants will be
covered.
4.2. Whole Genome and Exome Analysis. Since the comple-
tion of theHumanGenomeProject in 2001, sequencing of the
complete personal genome has become a technical reality [12,
13]. Since the initial assembly, the reference genome has been
re�ned and provided us initial insights in to the complexity
and extent of human genetic variation. Since then, initiatives
such as the 1000 Genomes Project aim to further characterize
human variation of all types in diﬀerent ethnic populations
[8]. Similar to exome sequencing, the true challenge of whole
genome analysis lies in the identi�cation of disease causing
mutations or functional SNPs among an average of 3.0–3.5
million SNVs and ∼1000CNVs in a human diploid genome
[12].
4.3. (Targeted) Whole Genome Sequencing. e current
feasibility of pharmacogenetic implementation of WGS data
has been shown in published personal genomes such as the
Lupski or the Venter genome [7, 12]. In both, several variants
were identi�ed with clinical pharmacogenetic signi�cance,
including warfarin or clopidogrel sensitivity. Another recent
example on how WGS can aid therapeutic treatment came
from a pair of twins suﬀering from dopa-responsive dysto-
nia. eir genomes were analyzed, and—assuming recessive
inheritance—the list of candidate genes was narrowed down
to three.One of thesewas sepiapterin (SPR), a gene previously
reported in association with DRD (OMIM no. 612716) but
so rare that no speci�c diagnostic test exists. Importantly,
patients with SPR mutations also have insuﬃcient tetrahy-
drobiopterin (BH4), an important cofactor in the biosynthesis
of dopamine and serotonin. Treatment of these patients
with L-dopa and 5-hydroxy-tryptophan resulted in marked
clinical improvement [32]. ough in this particular case
unrestricted WGS was applied, it can be conceived that
targeted WGS focussing on all genes known to be related to
DRD could be used to improve diagnostics and choose the
optimal treatment strategy.
4.4. Whole Genome Analysis as the Standard of Clinical Care.
One of the issues that has risen recently is whether the
characterization of the genomic sequence of an individual
should become the standard of care. is issue has great
relevance to the pediatric population, and several arguments
can be conceived why this data should or should not be
available as early on as possible, ideally in the neonatal period.
ere can be two rationales to gain knowledge of this
genomic information: the �rst would be to improve pre-
ventive medicine by identifying causal mutations or risk
alleles associated with so-called actionable diseases, that is,
diseases for which preventive measurements of screening
have been shown useful for improvement of prognosis.
Aer sequencing, the whole genome data set is completely
analyzed, with the intrinsic risk to also unveil risk alleles or
mutations for nonactionable disorders such as, for example,
neurodegenerative diseases.e second rationale would be to
have rapid access to the genetic background of an individual if
there is an acute disease episode, for diagnostic and pharma-
cogenetic purposes. is would imply that the uninterpreted
data is stored, and—when, for example, the patient develops
symptoms of asthma—the sequences of those genes known to
be involved in drug response of beta-agonists can be quickly
assembled and searched for variants thatmay guide treatment
options.
ough both scenarios can be seen as the ultimate re�ne-
ment of personalized medicine, there are several practical,
ethical, and legal considerations that need to be made before
this can be implemented, most of which also apply for WES.
4.5. Practical Issues. Besides technical issues related to stor-
age and access of the data and data analysis (method and
quality of analysis as well as the bioinformatic—hard- and
soware—capacities), the main practical issue remains the
interpretation of the sequence data (Figure 3) [7, 33–35].
e human genome is highly variable, with a diﬀerence
of each personal genome from the reference assembly in
3.5 million SNPs and 1000 large CNVs. Moreover, it is
considered that each personal genome contains 400.000 to
600.000 novel SNPs compared to databases such as dbSNP.
Moreover, not only the functional eﬀect of each individual
variant should be considered but also the interaction between
diﬀerent variants.is has, for example, been shown for copy
number variants, many of which can be found across genes
encoding proteins with known drug-metabolizing activity.
ese deletions and duplications can have a high prevalence
in the general population, ranging from 2% to 34%, and
individuals who are considered outlier metabolizers (poor
or ultra-metabolizers) were shown to harbor a high amount
of these CNVs (deletions and duplications, resp.). However,
the presence of such a CNV in a patient does not necessarily
mean that it will be predictable for the metabolizer status of
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Tx Tx Tx
Variant confirmation
and validation
Literature, databases, and so forth
F 3: Work�ow for pharmacogenomics using WES or WGS. A�er mapping to the reference sequence and variant calling, variants need
to be �ltered. Besides the known functional variants and the normal variations, it can be expected that a considerable number of novel variants
in genes involved in drug metabolism will be found. For these, additional functional assays will have to be performed to con�rm whether
they have functional relevance or not.
that patient. Besides the fact that many of these—particularly
duplications—may be nonfunctional, their eﬀect may be
compensated by other variants or regulatory mechanisms,
in the end leading to little change in the drug metabolism
of that individual. Hence, decision-making for, for example,
drug dosage based on this variant alone may result in under-
or overdosing. is leads to the conclusion that extensive
empirical evaluation of variants on drug metabolism in the
general population will be needed before they can be applied
in clinical routine and that postmarketing studies will also
need to address this issue.
4.6. Ethical and Legal Issues. Several ethical considerations
need to be made prior to routine clinical implementation, in
adults but particularly also in children. e huge amount of
personal medical data produced by NGS, the fact that some
will be irrelevant, that some may be relevant for diseases
beyond the primary reason for the test and that some may be
diﬃcult to interpret and hence unclear, make that all ethical
issues raised before on genetic testing now come together in
a single test [36].
A �rst issue is the consent. Because of its speci�c nature,
certainly WES and WGS require a diﬀerent kind of consent
compared to the routine genetic tests. As mentioned previ-
ously, a potential bene�t of these screening technologies for
the patient may be the early detection of actionable diseases,
the symptoms of which can occur in childhood. Besides
the obvious advantages for followup and prognosis, it must
be taken into account that being confronted unexpectedly
with the knowledge that the child may develop one or more
diseases can bring about signi�cant psychological burden for
the child and the parents. While this will be so for variants
associated with high risk to develop disease, -suddenly, an
additional medical track needs to be established for this
novel health problem-, the psychological eﬀect may be even
more pronouncedwhen a variant is discoveredwithmediocre
or low penetrance and hence increased uncertainty about
the future of the child. erefore, it seems imperative that
prior to WES or WGS for a given diagnostic question, the
patient and/or his parents are informed about other diseases
for which the test can reveal information and what the
implications can be of each of these.e consent that is given
will need to not only stipulate rigorously which diseases are
being (indirectly) looked at, but also mention the possibility
of variants of unknown signi�cance, of which it remains
uncertain what the eﬀectmay be. Needless to say that this will
require a much more extensive pretest counseling compared
to the molecular testing that is routinely used to date as well
as posttest (psychological) followup.
To respect the right of the child not to know, it has
been a standard policy not to perform presymptomatic tests
in children, when the onset of the disease is in adulthood
[34]. A broad screening assay such as untargeted WES or
WGS in the context of pharmacogenomics for a childhood
disease will also reveal information on these speci�c �late-
onset� diseases so that one can re�ect onwhether parentswho
give consent for this analysis have the right to disregard the
right not to know of their child. In contrast, the situationmay
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occur that a mutation of a late-onset disorder was inherited
from a parent who does not have any symptoms yet at the
moment of the test. When it concerns an actionable disease,
this knowledge may improve treatment and prognosis of this
individual and may play an important role in the decision-
making for future pregnancies. A similar situation may
arise regarding the carriership of mutations for autosomal
recessive disorders. Mutation analysis in obligate or potential
carriers is in most cases not performed in childhood, as
there are no implications for the health of the carrier, and
the child has the right to decide himself/herself whether he
or she wants to know their carrier status. Using untargeted
WES orWGS, carriership of several autosomal recessive traits
would be identi�ed in every patient analyzed. One could
argue to discard this information as it has no immediate
bene�t for the patient. On the other hand, this information
may be important for the parents—if theywould have another
child—and possibly other family members, particularly if the
carrier frequency in the general population is considerable.
Should the right not to know of the child overrule the
potential bene�t for the parents and other family members?
ese situations can be seen as a plea for targeted analysis,
as the risk for such incidental �ndings would be minimized.
ough this poses few problems when the sequence data
that is generated is limited to the genes of interest, but
when targeted analysis is performed on a larger sequence
data set—in the context of targeted WES or WGS—it should
be considered that all sequence data on actionable diseases,
although uninterpreted, is available. Does the child not have
the right to know whether other genetic information in his
genome is present for actionable diseases, the knowledge of
which may in�uence his health in a signi�cant manner? Or
correspondingly, does the physician or the diagnostic lab
not have the obligation to inform the patient? ough no
conclusive answer can be given to these questions at this
time, many uncertainties can be avoided if the informed
consent form stipulates in detail not only which tests will be
performed but also what will not be examined [37].
All issues mentioned previously underline that a thor-
ough debate addressing the medical, ethical, and psycho-
logical aspects of WES and WGS with respect to the child,
the parents and the rest of the family is necessary prior
to the diagnostic implementation of these techniques in,
for example, pharmacogenomics. Such debate has begun
to occur within the genetic community, and international
consensus and guidelines will need to be draed regarding
late-onset disorders, carriership of recessive diseases, and
actionable or non-actionable childhood diseases. However,
because of the extensive impact these screening strategies can
have, a more global public debate is necessary to inform the
public about these novel possibilities and their challenges and
to think about what people really want to learn from such a
genetic test when suﬃciently informed.
A second issue focusses on the interpretation of sequence
data. Should patients be informed of variants of uncertain
signi�cance? e main argument not to provide such details
is that it does not give additional information to the patient
at the time of consultation. However, as knowledge increases,
more may become known about these variants; this could
imply that what was once a variant of unknown signi�cance
may turn out to be of immediate relevance to the patients
health or that of his family members. Knowledge of these
variants, even when their meaning is initially unclear, may
be useful in the followup. In this respect, the question
whether the physician or diagnostic facility has the duty to
recontact patients when the interpretation of their sequence
data changes over the years has not been answered. If this
were to be the case, a fully automated informatics system
would be needed to regularly screen the stored genomic
data of every patient and match all variants with the current
literature. To our knowledge, such large-scale systems which
are �awless are not yet available, making the duty to recontact
for these large data sets nearly impossible at this time.
Legal issues that can arise aroundWES/WGS include the
storage and access of genomic sequence data and the question
of who can gain access: the individual himself, his treating
physician(s), insurance companies, police, and so forth [35].
Also gene patenting might become an important subject.
5. Conclusion
e technical revolution in sequencing analysis tools has lead
to new perspectives for personalized medicine in general and
in pharmacogenetics/genomics speci�cally. Next generation
sequencing and its applications have increased our ability to
unravel the genetic code of an individual with signi�cant
improvement of the speed of the analysis. On the other
hand, the implementation of these assays brings about sev-
eral considerations regarding sensitivity, data analysis, and
interpretation as well as ethical aspects. Of the current NGS
technologies, the array-based approach seems to be the most
feasible one for pharmacogenomic applications in childhood.
Its targeted nature avoids incidental �ndings while oﬀering
suﬃcient coverage of coding and noncoding regions of
genes of interest. With little doubt, the future perspective
will be the application of WGS as a diagnostic tool, also
in pharmacogenomics. However, many questions need to
be addressed before implementing this screening technique
in the clinic, including technical challenges, interpretation
diﬃculties, and ethical considerations. Most importantly,
the implementation of NGS requires the establishment of
genotypes with clinical utility and guidelines on how to use
them.ough the topic of research inmany areas, more eﬀort
will have to go to validating genotypic data and developing
clinical algorithms using them.
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